利妥昔单抗治疗套细胞淋巴瘤临床疗效分析(2)
 |
| 第1页 |
参见附件。
虽然很多新的治疗方法和新的药物不同程度的提高了套细胞淋巴瘤患者的CR 率,但仍然不能提高患者的长期生存率。我们迫切的需要研究出更多、更有效的治疗方案。我们期待着新的药物能够改变套细胞淋巴瘤治疗的尴尬局面,同时也希望更多的大样本的临床试验对现有的方案进行评估, 统一对套细胞淋巴瘤 治疗的认识确立一线的治疗方案。
参考文献
[1] Bertoni F,Zucca E,CotterFE.Molecular basi of mantle cell lymphoma.Br J Haematol,2004,124；130
[2] Lenz G,Dreyling M,Hoster E,el al.Immunochemotherapy with ritximab and cyclophosphamide,doxorubicin,vincristine,and prednisone significantly improves response and time to treatment failure,but not long-term outcom in patients with previously untreated mantle cell lymphoma:Result of a prospective randomized trialof the German Low Grade Lymphoma Study Group(GLSG).J Clin Oncol,2005,23(9):1984
[3] Fayad L,Thomas D,Romaguera J.Update of the M.D.Anderson Cancer Center experiece with hyper-CVAD and rituximab for the treatment of manlie cell and Burkitt-type lymphomas[J].Clin Lymphoma Myeloma,2007,8Suppl 2:S57-62
[4] Thomas DW,Owen RG,Johnson SA,et al.Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP.Leuk lymph,2005,46(4):549
作者单位：410013 湖南省长沙市湖南省肿瘤医院
您现在查看是摘要介绍页，详见PDF附件(3974kb)。